期刊
HEPATOLOGY
卷 76, 期 3, 页码 742-758出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/hep.32332
关键词
-
资金
- National Key Research and Development Program of China [2016YFA0102100, 2021YFA1100500]
- NSFC [81970814, 81800533, 81870430, 81422009, 81770560]
This study investigates the role of endothelial Notch signaling in the development of NASH. The results show that activation of Notch signaling in endothelial cells leads to LSEC maladaptation and worsens NASH symptoms, while inhibition of Notch signaling restores LSEC homeostasis and improves NASH phenotypes. Furthermore, the study reveals that Notch activation exacerbates NASH by inhibiting eNOS transcription, and administration of an eNOS activator alleviates hepatic steatosis and lipid accumulation resulting from Notch activation. Finally, the study demonstrates the potential therapeutic effect of Notch inhibitors in treating NASH.
Background and Aims Although NASH can lead to severe clinical consequences, including cirrhosis and hepatocellular carcinoma, no effective treatment is currently available for this disease. Increasing evidence indicates that LSECs play a critical role in NASH pathogenesis; however, the mechanisms involved in LSEC-mediated NASH remain to be fully elucidated. Approach and Results In the current study, we found that LSEC homeostasis was disrupted and LSEC-specific gene profiles were altered in methionine-choline-deficient (MCD) diet-induced NASH mouse models. Importantly, Notch signaling was found to be activated in LSECs of NASH mice. To then investigate the role of endothelial Notch in NASH progression, we generated mouse lines with endothelial-specific Notch intracellular domain (NICD) overexpression or RBP-J knockout to respectively activate or inhibit Notch signaling in endothelial cells. Notably, endothelial-specific overexpression of the NICD accelerated LSEC maladaptation and aggravated NASH, whereas endothelial cell-specific inhibition of Notch signaling restored LSEC homeostasis and improved NASH phenotypes. Furthermore, we demonstrated that endothelial-specific Notch activation exacerbated NASH by inhibiting endothelial nitric oxide synthase (eNOS) transcription, whereas administration of the pharmacological eNOS activator YC-1 alleviated hepatic steatosis and lipid accumulation resulting from Notch activation. Finally, to explore the therapeutic potential of using Notch inhibitors in NASH treatment, we applied two gamma-secretase inhibitors-DAPT and LY3039478-in an MCD diet-induced mouse model of NASH, and found that both inhibitors effectively ameliorated hepatic steatosis, inflammation, and liver fibrosis. Conclusions Endothelial-specific Notch activation triggered LSEC maladaptation and exacerbated NASH phenotypes in an eNOS-dependent manner. Genetic and pharmacological inhibition of Notch signaling effectively restored LSEC homeostasis and ameliorated NASH progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据